Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction: A Double-blind Randomized Controlled Phase IV Trial (VASCEND)

NCT03168568 is registered in ClinicalTrials.gov with University of Zurich as lead sponsor.

NCT NCT03168568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03168568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction: A Double-blind Randomized Controlled Phase IV Trial (VASCEND)
Lead sponsor
University of Zurich
Phase
Phase 4
Overall status
Completed
Start date
May 4, 2017
Completion date
September 5, 2020
Enrollment
79 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure